HOUSTON & NEW YORK--(BUSINESS WIRE)--The High Q Foundation Inc. (High Q), a foundation that supports research aimed at finding treatments for Huntington’s disease, and Stem Cell Innovations, Inc. (SCI) (OTCBB: SCLL) announced today that they have entered into a two-year R&D alliance. The organizations will apply SCI’s PluriCells™ to develop Huntington’s disease specific human cell systems for the purpose of drug discovery. Under the terms of their agreement, SCI will receive up to $1.1 million from High Q upon completion of certain milestones. In addition, SCI has the right to further use, develop and commercialise the outcome of the project.
